脂蛋白(a)、PCSK9抑制与心血管风险
FOURIER试验中,25 096例确诊动脉粥样硬化性心血管疾病患者随机接受evolocumab或安慰剂,中位随访2.2年。基线Lp(a)最高四分位者冠心病死亡、心肌梗死或紧急血运重建风险升高(校正HR 1.22;95%CI 1.01-1.48),独立于LDL-C;evolocumab显著降低Lp(a)中位26.9%,基线Lp(a)>中位数者冠心病风险降低23%,≤中位数者降低7%(交互P=0.07)。
要点
- 基线Lp(a)最高四分位者冠心病事件风险升高22%,独立于LDL-C。
- evolocumab使Lp(a)中位降低26.9%,与LDL-C降幅中度正相关(r=0.37)。
- 基线Lp(a)>中位数者冠心病风险降低23%,绝对风险降低2.49%,3年NNT=40。
核心结论
- 在确诊动脉粥样硬化性心血管疾病患者中,较高Lp(a)水平与心血管事件风险增加独立于LDL-C相关。
- evolocumab显著降低Lp(a)水平,基线Lp(a)较高者绝对风险降低更大,倾向于从PCSK9抑制中获得更大冠状动脉获益。
研究设计与样本
- FOURIER试验(NCT01764633)为随机对照试验,比较evolocumab与安慰剂在确诊动脉粥样硬化性心血管疾病患者中的疗效。
- 共纳入25 096例患者,测量Lp(a),中位随访2.2年,采用Cox模型评估Lp(a)的独立预后价值及evolocumab按基线Lp(a)分层的疗效。
主要发现
- 基线Lp(a)中位数(四分位距)为37(13-165)nmol/L。
- 安慰剂组中,基线Lp(a)最高四分位者冠心病死亡、心肌梗死或紧急血运重建风险较高(校正HR 四分位4 vs 四分位1:1.22;95%CI 1.01-1.48),独立于LDL-C。
- 48周时,evolocumab使Lp(a)中位降低26.9%(四分位距6.2%-46.7%)。
- 48周时evolocumab组Lp(a)与LDL-C百分比变化呈中度正相关(r=0.37;95%CI 0.36-0.39;P<0.001)。
- evolocumab使基线Lp(a)>中位数者冠心病死亡、心肌梗死或紧急血运重建风险降低23%(HR 0.77;95%CI 0.67-0.88),≤中位数者降低7%(HR 0.93;95%CI 0.80-1.08;交互P=0.07)。
关键数值与推荐
- 基线Lp(a)最高四分位 vs 最低四分位:校正HR 1.22(95%CI 1.01-1.48)。
- evolocumab降低Lp(a)中位26.9%(四分位距6.2%-46.7%)。
- Lp(a)与LDL-C变化相关性:r=0.37(95%CI 0.36-0.39;P<0.001)。
- 基线Lp(a)>中位数:HR 0.77(95%CI 0.67-0.88),绝对风险降低2.49%,3年NNT=40;≤中位数:HR 0.93(95%CI 0.80-1.08),绝对风险降低0.95%,3年NNT=105;交互P=0.07。
临床怎么用
- 在确诊动脉粥样硬化性心血管疾病患者中,可考虑检测基线Lp(a)以协助风险评估。
- 对于基线Lp(a)较高的患者,PCSK9抑制剂evolocumab可能带来更大的绝对冠状动脉获益。
局限性
- 中位随访2.2年,长期获益需进一步验证。
- 基线Lp(a)>中位数与≤中位数亚组间交互P=0.07,未达传统统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined. METHODS: Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years). Cox models were used to assess the independent prognostic value of Lp(a) and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration. RESULTS: The median (interquartile range) baseline Lp(a) concentration was 37 (13-165) nmol/L. In the placebo arm, patients with baseline Lp(a) in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol. At 48 weeks, evolocumab significantly reduced Lp(a) by a median (interquartile range) of 26.9% (6.2%-46.7%). The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking evolocumab was moderately positively correlated ( r=0.37; 95% CI, 0.36-0.39; P<0.001). Evolocumab reduced the risk of coronary heart disease death, myocardial infarction, or urgent revascularization by 23% (hazard ratio, 0.77; 95% CI, 0.67-0.88) in patients with a baseline Lp(a) >median, and by 7% (hazard ratio, 0.93; 95% CI, 0.80-1.08; P interaction=0.07) in those ≤median. Coupled with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years were 2.49% and 40 versus 0.95% and 105, respectively. CONCLUSIONS: Higher levels of Lp(a) are associated with an increased risk of cardiovascular events in patients with established cardiovascular disease irrespective of low-density lipoprotein cholesterol. Evolocumab significantly reduced Lp(a) levels, and patients with higher baseline Lp(a) levels experienced greater absolute reductions in Lp(a) and tended to derive greater coronary benefit from PCSK9 inhibition. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633.
引用
- O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019. PMID: 30586750. doi:10.1161/CIRCULATIONAHA.118.037184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。